[
  {
    "ts": "2025-12-02T06:06:52+00:00",
    "headline": "Morgan Stanley Bullish on Eli Lilly and Company (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best dividend stocks to buy according to hedge funds. On November 23, Morgan Stanley analyst Terence Flynn maintained a Buy call on Eli Lilly, along with a price target of $1,290. In a different corporate update, dated November 24, Eli Lilly reported that it will present […]",
    "url": "https://finance.yahoo.com/news/morgan-stanley-bullish-eli-lilly-060652835.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f0366cbf-0525-3273-921a-668a982e8d2e",
      "content": {
        "id": "f0366cbf-0525-3273-921a-668a982e8d2e",
        "contentType": "STORY",
        "title": "Morgan Stanley Bullish on Eli Lilly and Company (LLY)",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best dividend stocks to buy according to hedge funds. On November 23, Morgan Stanley analyst Terence Flynn maintained a Buy call on Eli Lilly, along with a price target of $1,290. In a different corporate update, dated November 24, Eli Lilly reported that it will present […]",
        "pubDate": "2025-12-02T06:06:52Z",
        "displayTime": "2025-12-02T06:06:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347",
          "originalWidth": 1920,
          "originalHeight": 1186,
          "caption": "Morgan Stanley Bullish on Eli Lilly and Company (LLY)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vJ7lKbloSPByVfgD_gqgZg--~B/aD0xMTg2O3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347.cf.webp",
              "width": 1920,
              "height": 1186,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/szs6fG45A8w_rlV8N_NBzA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-bullish-eli-lilly-060652835.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/morgan-stanley-bullish-eli-lilly-060652835.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T09:10:00+00:00",
    "headline": "Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034",
    "summary": "Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth. Abemaciclib Market Abemaciclib Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The \"Abemaciclib Market Report 2025\" report has been added to ResearchAndMarkets.c",
    "url": "https://finance.yahoo.com/news/abemaciclib-research-report-2025-eli-091000083.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "5eef4f6a-2e93-3003-8163-d88f1ecb934a",
      "content": {
        "id": "5eef4f6a-2e93-3003-8163-d88f1ecb934a",
        "contentType": "STORY",
        "title": "Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034",
        "description": "",
        "summary": "Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth. Abemaciclib Market Abemaciclib Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The \"Abemaciclib Market Report 2025\" report has been added to ResearchAndMarkets.c",
        "pubDate": "2025-12-02T09:10:00Z",
        "displayTime": "2025-12-02T09:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/ddda3a59e715735ec1b7407ff5a69bde",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Abemaciclib Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SDRIcd63m_N9hqFIRHH3zw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/ddda3a59e715735ec1b7407ff5a69bde.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CiKDL_6RVKlUCm40O2GT3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/ddda3a59e715735ec1b7407ff5a69bde.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abemaciclib-research-report-2025-eli-091000083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abemaciclib-research-report-2025-eli-091000083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T13:21:00+00:00",
    "headline": "Best-Performing ETFs of November",
    "summary": "November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.",
    "url": "https://finance.yahoo.com/news/best-performing-etfs-november-132100056.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6d1ec5cf-2298-3283-9c7d-369ff6f76609",
      "content": {
        "id": "6d1ec5cf-2298-3283-9c7d-369ff6f76609",
        "contentType": "STORY",
        "title": "Best-Performing ETFs of November",
        "description": "",
        "summary": "November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.",
        "pubDate": "2025-12-02T13:21:00Z",
        "displayTime": "2025-12-02T13:21:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/49b19d5f77c2e6fb2ac483c58199d712",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MSRJWsL.FtoslgXQOYcRCw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/49b19d5f77c2e6fb2ac483c58199d712.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JYRdp73DKH_vnywdUjFJHg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/49b19d5f77c2e6fb2ac483c58199d712.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/best-performing-etfs-november-132100056.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/best-performing-etfs-november-132100056.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "UNG"
            },
            {
              "symbol": "OZEM"
            },
            {
              "symbol": "SPYM"
            },
            {
              "symbol": "WNTR"
            },
            {
              "symbol": "LITP"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BWET"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]